Abstract 4768: Development of fully human TCR-mimic antibodies targeting intracellular tumor antigens using humanized RenTCR-mimic transgenic mice
Abstract T cell receptors (TCRs), a promising therapeutic strategy for targeting intracellular antigens, can specifically recognize antigen peptide presented by human lymphocyte antigen (HLA) and mediate T cell responses to eliminate tumor cells. However, the low affinity of TCRs presents a great challenge to their broader clinical application. TCR-mimic (TCRm) antibodies, with similar antigen recognition capabilities as TCRs but higher affinity, offer a solution to these limitations, enabling the targeting of previously undruggable cancer antigens. Neverthelss, specificity remains a major challenge to ensure therapeutic accuracy and patient safety, as TCRm antibodies need to precisely target a single tumor-specific peptide antigen presented by HLA rather than other similar peptides. Using RenTCR-mimic transgenic mice, we describe the generation and preclinical evaluation of fully human TCRm antibodies by fusing them with a humanized anti-CD3 scFv to form T cell engager or assembled on T cell surface to build TCRm-T cells, further to specifically redirect T cells to lysis tumors by our proprietary RenTCR-mimic platform. We determine cross-reactive peptide sequences predicted by in silico or known off-target sequences. We further confirm the specificity and safety of TCRm antibodies. Despite low density antigen copies, TCRm antibodies elicited antibody-mediated T-cell recognition and cytotoxicity against antigen peptide-HLA complexes-restricted cell lines. Based on these methods, we perform screens to validate TCRm antibodies specificity. These experiments led us to discriminate between the target peptide and the potential off-target peptides presented by HLA and highlight the therapeutics potential of TCRm antibodies in tumor immunotherapy, offering a novel approach to expanding the repertoire of druggable cancer targets. Citation Format: Han Zhang, Wanbo Tang, Jun Du, Yue Zhang, Limin Zhao, Xin Jiao, Baihong Liu, Yi Yang. Development of fully human TCR-mimic antibodies targeting intracellular tumor antigens using humanized RenTCR-mimic transgenic mice [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 4768.
Authors
- Wanbo Tang
- Limin Zhao (ORCID: https://orcid.org/0000-0002-6898-5331)
- Baihong Liu
- Han Zhang (ORCID: https://orcid.org/0000-0002-9101-4170)
- Jun Du (ORCID: https://orcid.org/0000-0002-2410-2429)
- Xin Jiao
- Yue Zhang (ORCID: https://orcid.org/0000-0003-1254-6222)
- Yi Yang (ORCID: https://orcid.org/0009-0001-5024-368X)
Institutions
- Beijing Biocytogen (China) (CN)
Publication Details
- Journal
- Cancer Research
- Published
- 2025-04-21
- DOI
- https://doi.org/10.1158/1538-7445.am2025-4768
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00